Compare CULP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | ACET |
|---|---|---|
| Founded | 1972 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 93.5M |
| IPO Year | N/A | N/A |
| Metric | CULP | ACET |
|---|---|---|
| Price | $3.63 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 38.7K | ★ 2.3M |
| Earning Date | 12-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,919,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $0.45 |
| 52 Week High | $5.94 | $1.11 |
| Indicator | CULP | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 30.48 |
| Support Level | $3.60 | $0.50 |
| Resistance Level | $3.82 | $0.59 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 5.26 | 4.67 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.